Mirum Pharmaceuticals (MIRM)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Liver Diseasesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 23/100 (LOW), 21.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 13.31% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum tees up Livmarli label expansion on Phase III liver disease study success
- Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
- Mirum gains as Phase 3 LIVMARLI trial meets primary endpoint in liver disease
- Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
- Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study
- PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Time-Varying Impact of Steatosis and Alcohol on Mortality: A Marginal Structural Model of the Canadian Longitudinal Study on Aging. — Liver Int 2026 Sep PMID 42557925
- Evaluating the relationship between antidrug antibodies and efficacy and safety outcomes in patients with Fabry disease receiving enzyme replacement therapy: a systematic literature review. — Orphanet J Rare Dis 2026 Jul 16 PMID 42464344
- Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program. — Open Forum Infect Dis 2026 Jul PMID 42388826
- Clinical evaluation of the Altostar HDV RT-PCR Kit 1.5. — J Clin Virol 2026 Aug PMID 42385559
- From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management. — Liver Int 2026 Aug PMID 42358056
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Mirum Pharmaceuticals.
Full MIRM Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.